Pilot trial of paclitaxel-trastuzumab adjuvant therapy for early stage breast cancer: a trial of the ECOG-ACRIN cancer research group (E2198)
about
Multi-arm Cost-Effectiveness Analysis (CEA) comparing different durations of adjuvant trastuzumab in early breast cancer, from the English NHS payer perspective.Suberoylanilide hydroxamic acid sensitizes neuroblastoma to paclitaxel by inhibiting thioredoxin-related protein 14-mediated autophagy.Effectiveness of trastuzumab as adjuvant therapy in patients with early stage breast cancer: A systematic review and meta-analysis.Optimizing (neo)adjuvant treatment of HER2-positive breast cancer
P2860
Pilot trial of paclitaxel-trastuzumab adjuvant therapy for early stage breast cancer: a trial of the ECOG-ACRIN cancer research group (E2198)
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh
2015年學術文章
@zh-hant
name
Pilot trial of paclitaxel-tras ...... cancer research group (E2198)
@ast
Pilot trial of paclitaxel-tras ...... cancer research group (E2198)
@en
type
label
Pilot trial of paclitaxel-tras ...... cancer research group (E2198)
@ast
Pilot trial of paclitaxel-tras ...... cancer research group (E2198)
@en
prefLabel
Pilot trial of paclitaxel-tras ...... cancer research group (E2198)
@ast
Pilot trial of paclitaxel-tras ...... cancer research group (E2198)
@en
P2093
P2860
P356
P1476
Pilot trial of paclitaxel-tras ...... cancer research group (E2198)
@en
P2093
Ann D Thor
Anne O'Neill
Bryan P Schneider
George W Sledge
Nancy E Davidson
Paul J Zander
Stephen P Kahanic
P2860
P2888
P304
P356
10.1038/BJC.2015.405
P407
P577
2015-12-01T00:00:00Z
P6179
1005070904